TAK-875 Glimepiride Drug-Interaction Study
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 30
Summary
- Conditions
- Pharmacokinetics
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: Single (Participant)
Participation Requirements
- Age
- Between 18 years and 68 years
- Gender
- Both males and females
Description
TAK-875 is being developed at Takeda Global Research and Development, Inc. as an adjunct to diet and exercise to improve glycemic control in participants with T2DM. This study will determine whether administration of glimepiride alters the pharmacokinetics (PK) of TAK-875, and whether TAK-875 affect...
TAK-875 is being developed at Takeda Global Research and Development, Inc. as an adjunct to diet and exercise to improve glycemic control in participants with T2DM. This study will determine whether administration of glimepiride alters the pharmacokinetics (PK) of TAK-875, and whether TAK-875 affects the PK of glimepiride.
Tracking Information
- NCT #
- NCT01496443
- Collaborators
- Not Provided
- Investigators
- Study Director: Senior Medical Director, Clinical Science Takeda
Get Well Soon